Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 

RXULTI Film-coated tablet (2020)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

RXULTI 0.25 mg film-coated tablets. RXULTI 0.5 mg film-coated tablets. RXULTI 1 mg film-coated tablets. RXULTI 2 mg film-coated tablets. RXULTI 3 mg film-coated tablets. RXULTI 4 mg film-coated tablets. ...

Qualitative and quantitative composition

RXULTI 0.25 mg film-coated tablets: Each film-coated tablet contains 0.25 mg brexpiprazole. Excipient with known effect: Each film-coated tablet contains 48.2 mg lactose (as monohydrate). RXULTI 0.5 mg ...

Pharmaceutical form

Film-coated tablet. RXULTI 0.25 mg film-coated tablets: Light brown, round, 6 mm in diameter, shallow convex and bevel-edged, debossed with BRX and 0.25 on one side. RXULTI 0.5 mg film-coated tablets: ...

Therapeutic indications

RXULTI is indicated for the treatment of schizophrenia in adult patients.

Posology and method of administration

Posology The recommended starting dose for brexpiprazole is 1 mg once daily on days 1 to 4. The recommended target dose range is 2 mg to 4 mg once daily. Based on the patients clinical response and tolerability ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

During antipsychotic treatment, improvement in the patients clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period. Suicidal ideation and behaviour ...

Interaction with other medicinal products and other forms of interaction

Brexpiprazole is predominantly metabolised by CYP3A4 and CYP2D6. Potential for other medicinal products to affect brexpiprazole CYP3A4 inhibitors Co-administration of ketoconazole (200 mg twice daily for ...

Fertility, pregnancy and lactation

Pregnancy There are no or limited amount of data from the use of brexpiprazole in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Brexpiprazole is not recommended ...

Effects on ability to drive and use machines

Brexpiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system effects, such as sedation and dizziness that are common adverse drug reactions (see ...

Undesirable effects

Summary of the safety profile The most frequently observed adverse drug reactions (ADRs) were akathisia (5.6%) and weight gain (3.9%). Tabulated list of adverse reactions The incidences of the ADRs associated ...

Overdose

Gastric lavage and treatment with an emetic may be useful immediately after overdose. An electrocardiogram should be obtained in case of overdose and if QT interval prolongation is present, cardiac monitoring ...

Pharmacodynamic properties

Pharmacotherapeutic group: Psycholeptics, other antipsychotics ATC code: N05AX16 Mechanism of action Brexpiprazole is an atypical antipsychotic agent. The pharmacology of brexpiprazole is believed to be ...

Pharmacokinetic properties

Absorption Brexpiprazole is absorbed after administration of the tablet, with peak plasma concentrations occurring within 4.0 hours after single dose administrations; the absolute oral bioavailability ...

Preclinical safety data

Effects observed in repeated-dose toxicity studies in rats and monkeys were mainly related to the exaggerated pharmacological activity of brexpiprazole. No safety margins based on AUC<sub>0-24h</sub> at ...

List of excipients

Tablet core: Lactose monohydrate Maize starch Microcrystalline cellulose Low-substituted hydroxypropylcellulose Hydroxypropylcellulose Magnesium stearate Purified water Tablet coat: Hypromellose Talc ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

RXULTI 0.25 mg, 0.5 mg, 2 mg, 3 mg and 4 mg film-coated tablets: 28 film-coated tablets in Aluminium/PVC blisters. RXULTI 1 mg film-coated tablets: 10 or 28 film-coated tablets in Aluminium/PVC blisters. ...

Special precautions for disposal and other handling

This medicinal product may pose a risk to the environment (see section 5.3). Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT, Amsterdam, Netherlands

Marketing authorization number(s)

RXULTI 0.25 mg film-coated tablets: EU/1/18/1294/001 (28 film-coated tablets) RXULTI 0.5 mg film-coated tablets: EU/1/18/1294/002 (28 film-coated tablets) RXULTI 1 mg film-coated tablets: EU/1/18/1294/003 ...

Date of first authorization / renewal of the authorization

Date of first authorisation: 26 July 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: